Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Therapeutic targeting of TGF-β ligands in glioblastoma using novel antisense oligonucleotides reduces the growth of experimental gliomas.

Papachristodoulou A, Silginer M, Weller M, Schneider H, Hasenbach K, Janicot M, Roth P.

Clin Cancer Res. 2019 Sep 17. pii: clincanres.3024.2017. doi: 10.1158/1078-0432.CCR-17-3024. [Epub ahead of print]

PMID:
31530630
2.

First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery.

Pfeiffer N, Voykov B, Renieri G, Bell K, Richter P, Weigel M, Thieme H, Wilhelm B, Lorenz K, Feindor M, Wosikowski K, Janicot M, Päckert D, Römmich R, Mala C, Fettes P, Leo E.

PLoS One. 2017 Nov 30;12(11):e0188899. doi: 10.1371/journal.pone.0188899. eCollection 2017.

3.

An antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages.

Huber-Ruano I, Raventós C, Cuartas I, Sánchez-Jaro C, Arias A, Parra JL, Wosikowski K, Janicot M, Seoane J.

Ann Oncol. 2017 Sep 1;28(9):2278-2285. doi: 10.1093/annonc/mdx314.

PMID:
28911087
4.

Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma.

Seystahl K, Papachristodoulou A, Burghardt I, Schneider H, Hasenbach K, Janicot M, Roth P, Weller M.

Mol Cancer Ther. 2017 Jun;16(6):1177-1186. doi: 10.1158/1535-7163.MCT-16-0465. Epub 2017 Apr 4.

5.

TGF-β1 and TGF-β2 abundance in liver diseases of mice and men.

Dropmann A, Dediulia T, Breitkopf-Heinlein K, Korhonen H, Janicot M, Weber SN, Thomas M, Piiper A, Bertran E, Fabregat I, Abshagen K, Hess J, Angel P, Coulouarn C, Dooley S, Meindl-Beinker NM.

Oncotarget. 2016 Apr 12;7(15):19499-518. doi: 10.18632/oncotarget.6967.

6.

TGF-ß isoforms in cancer: Immunohistochemical expression and Smad-pathway-activity-analysis in thirteen major tumor types with a critical appraisal of antibody specificity and immunohistochemistry assay validity.

Riemenschneider MJ, Hirblinger M, Vollmann-Zwerenz A, Hau P, Proescholdt MA, Jaschinski F, Rothhammer-Hampl T, Wosikowski K, Janicot M, Leo E.

Oncotarget. 2015 Sep 29;6(29):26770-81. doi: 10.18632/oncotarget.5780.

7.

Design and Selection of Antisense Oligonucleotides Targeting Transforming Growth Factor Beta (TGF-β) Isoform mRNAs for the Treatment of Solid Tumors.

Jaschinski F, Korhonen H, Janicot M.

Methods Mol Biol. 2015;1317:137-51. doi: 10.1007/978-1-4939-2727-2_9.

PMID:
26072406
8.

Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts.

Chargari C, Leteur C, Angevin E, Bashir T, Schoentjes B, Arts J, Janicot M, Bourhis J, Deutsch E.

Cancer Lett. 2011 Dec 22;312(2):209-18. doi: 10.1016/j.canlet.2011.08.011. Epub 2011 Aug 22.

PMID:
21937165
9.

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJ.

Pediatr Blood Cancer. 2012 Aug;59(2):329-32. doi: 10.1002/pbc.23319. Epub 2011 Sep 15.

10.

Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.

Angibaud P, Van Emelen K, Decrane L, van Brandt S, Ten Holte P, Pilatte I, Roux B, Poncelet V, Speybrouck D, Queguiner L, Gaurrand S, Mariën A, Floren W, Janssen L, Verdonck M, van Dun J, van Gompel J, Gilissen R, Mackie C, Du Jardin M, Peeters J, Noppe M, Van Hijfte L, Freyne E, Page M, Janicot M, Arts J.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):294-8. doi: 10.1016/j.bmcl.2009.10.118. Epub 2009 Oct 30.

PMID:
19906529
11.

JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.

Arts J, King P, Mariën A, Floren W, Beliën A, Janssen L, Pilatte I, Roux B, Decrane L, Gilissen R, Hickson I, Vreys V, Cox E, Bol K, Talloen W, Goris I, Andries L, Du Jardin M, Janicot M, Page M, van Emelen K, Angibaud P.

Clin Cancer Res. 2009 Nov 15;15(22):6841-51. doi: 10.1158/1078-0432.CCR-09-0547. Epub 2009 Oct 27.

12.

Delivery of a DNAzyme targeting c-myc to HT29 colon carcinoma cells using a gold nanoparticulate approach.

Tack F, Noppe M, Van Dijck A, Dekeyzer N, Van Der Leede BJ, Bakker A, Wouters W, Janicot M, Brewster ME.

Pharmazie. 2008 Mar;63(3):221-5.

PMID:
18444511
13.

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.

Arts J, Angibaud P, Mariën A, Floren W, Janssens B, King P, van Dun J, Janssen L, Geerts T, Tuman RW, Johnson DL, Andries L, Jung M, Janicot M, van Emelen K.

Br J Cancer. 2007 Nov 19;97(10):1344-53. Epub 2007 Nov 13.

14.

Dendrimeric poly(propylene-imines) as effective delivery agents for DNAzymes: toxicity, in vitro transfection and in vivo delivery.

Tack F, Bakker A, Maes S, Dekeyser N, Bruining M, Elissen-Roman C, Janicot M, Janssen HM, De Waal BF, Fransen PM, Lou X, Meijer EW, Arien A, Brewster ME.

J Control Release. 2006 Nov 28;116(2):e26-8. No abstract available.

PMID:
17718951
15.

Dendrimeric poly(propylene-imines) as effective delivery agents for DNAzymes: dendrimer synthesis, stability and oligonucleotide complexation.

Tack F, Bakker A, Maes S, Dekeyser N, Bruining M, Elissen-Roman C, Janicot M, Janssen HM, De Waal BF, Fransen PM, Lou X, Meijer EW, Arien A, Brewster ME.

J Control Release. 2006 Nov 28;116(2):e24-6. No abstract available.

PMID:
17718950
16.

Real-time gene expression analysis in human xenografts for evaluation of histone deacetylase inhibitors.

Beliën A, De Schepper S, Floren W, Janssens B, Mariën A, King P, Van Dun J, Andries L, Voeten J, Bijnens L, Janicot M, Arts J.

Mol Cancer Ther. 2006 Sep;5(9):2317-23.

17.

Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells.

VanderBorght A, Valckx A, Van Dun J, Grand-Perret T, De Schepper S, Vialard J, Janicot M, Arts J.

Oncogene. 2006 Oct 26;25(50):6672-7. Epub 2006 May 29.

PMID:
16732328
18.

The Wnt-dependent signaling pathways as target in oncology drug discovery.

Janssens N, Janicot M, Perera T.

Invest New Drugs. 2006 Jul;24(4):263-80. Review.

19.

Modified poly(propylene imine) dendrimers as effective transfection agents for catalytic DNA enzymes (DNAzymes).

Tack F, Bakker A, Maes S, Dekeyser N, Bruining M, Elissen-Roman C, Janicot M, Brewster M, Janssen HM, De Waal BF, Fransen PM, Lou X, Meijer EW.

J Drug Target. 2006 Feb;14(2):69-86.

PMID:
16608734
20.

p53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2.

Aliouat-Denis CM, Dendouga N, Van den Wyngaert I, Goehlmann H, Steller U, van de Weyer I, Van Slycken N, Andries L, Kass S, Luyten W, Janicot M, Vialard JE.

Mol Cancer Res. 2005 Nov;3(11):627-34.

21.

Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth.

Jenkins Y, Markovtsov V, Lang W, Sharma P, Pearsall D, Warner J, Franci C, Huang B, Huang J, Yam GC, Vistan JP, Pali E, Vialard J, Janicot M, Lorens JB, Payan DG, Hitoshi Y.

Mol Biol Cell. 2005 Dec;16(12):5621-9. Epub 2005 Sep 29.

22.

Disruption of murine Mus81 increases genomic instability and DNA damage sensitivity but does not promote tumorigenesis.

Dendouga N, Gao H, Moechars D, Janicot M, Vialard J, McGowan CH.

Mol Cell Biol. 2005 Sep;25(17):7569-79.

23.

Design and analysis of drug combination experiments.

Straetemans R, O'Brien T, Wouters L, Van Dun J, Janicot M, Bijnens L, Burzykowski T, Aerts M.

Biom J. 2005 Jun;47(3):299-308.

PMID:
16053254
24.

Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors.

Angibaud P, Arts J, Van Emelen K, Poncelet V, Pilatte I, Roux B, Van Brandt S, Verdonck M, De Winter H, Ten Holte P, Marien A, Floren W, Janssens B, Van Dun J, Aerts A, Van Gompel J, Gaurrand S, Queguiner L, Argoullon JM, Van Hijfte L, Freyne E, Janicot M.

Eur J Med Chem. 2005 Jun;40(6):597-606. Epub 2005 Mar 3.

PMID:
15922843
25.

Alteration of frizzled expression in renal cell carcinoma.

Janssens N, Andries L, Janicot M, Perera T, Bakker A.

Tumour Biol. 2004 Jul-Aug;25(4):161-71.

PMID:
15557753
26.

Housekeeping genes as internal standards in cancer research.

Janssens N, Janicot M, Perera T, Bakker A.

Mol Diagn. 2004;8(2):107-13.

PMID:
15527325
27.

Assay development for high throughput screening of p21(Waf1/Cip1) protein expression in intact cells using fluorometric microvolume assay technology.

Grand-Perret T, Cik M, Arts J, Vander Borght A, Ercken M, Valckx A, Vermeesen A, Roevens R, Janicot M.

Drugs Exp Clin Res. 2004;30(3):89-98.

PMID:
15366785
28.

Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles.

Pun SH, Tack F, Bellocq NC, Cheng J, Grubbs BH, Jensen GS, Davis ME, Brewster M, Janicot M, Janssens B, Floren W, Bakker A.

Cancer Biol Ther. 2004 Jul;3(7):641-50. Epub 2004 Jul 9.

PMID:
15136766
29.

R176502, a new bafilolide metabolite with potent antiproliferative activity from a novel Micromonospora species.

Laakso JA, Mocek UM, Van Dun J, Wouters W, Janicot M.

J Antibiot (Tokyo). 2003 Nov;56(11):909-16.

30.

Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors.

Angibaud P, Bourdrez X, End DW, Freyne E, Janicot M, Lezouret P, Ligny Y, Mannens G, Damsch S, Mevellec L, Meyer C, Muller P, Pilatte I, Poncelet V, Roux B, Smets G, Van Dun J, Van Remoortere P, Venet M, Wouters W.

Bioorg Med Chem Lett. 2003 Dec 15;13(24):4365-9.

PMID:
14643327
31.

Cellular localization and antiproliferative effect of peptides discovered from a functional screen of a retrovirally delivered random peptide library.

Hitoshi Y, Gururaja T, Pearsall DM, Lang W, Sharma P, Huang B, Catalano SM, McLaughlin J, Pali E, Peelle B, Vialard J, Janicot M, Wouters W, Luyten W, Bennett MK, Anderson DC, Payan DG, Lorens JB, Bogenberger J, Demo S.

Chem Biol. 2003 Oct;10(10):975-87. No abstract available.

PMID:
14583264
32.

Cellular interacting proteins of functional screen-derived antiproliferative and cytotoxic peptides discovered using shotgun peptide sequencing.

Gururaja T, Li W, Catalano S, Bogenberger J, Zheng J, Keller B, Vialard J, Janicot M, Li L, Hitoshi Y, Payan DG, Anderson DC.

Chem Biol. 2003 Oct;10(10):927-37. No abstract available.

PMID:
14583259
33.

Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin.

De Schepper S, Bruwiere H, Verhulst T, Steller U, Andries L, Wouters W, Janicot M, Arts J, Van Heusden J.

J Pharmacol Exp Ther. 2003 Feb;304(2):881-8.

PMID:
12538846
34.

Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity.

Van Heusden J, Van Ginckel R, Bruwiere H, Moelans P, Janssen B, Floren W, van der Leede BJ, van Dun J, Sanz G, Venet M, Dillen L, Van Hove C, Willemsens G, Janicot M, Wouters W.

Br J Cancer. 2002 Feb 12;86(4):605-11.

35.

p53-dependent G2 arrest associated with a decrease in cyclins A2 and B1 levels in a human carcinoma cell line.

Badie C, Bourhis J, Sobczak-Thépot J, Haddada H, Chiron M, Janicot M, Janot F, Tursz T, Vassal G.

Br J Cancer. 2000 Feb;82(3):642-50.

36.

Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment.

Russell JS, Lang FF, Huet T, Janicot M, Chada S, Wilson DR, Tofilon PJ.

Cancer Res. 1999 Oct 15;59(20):5239-44.

37.

Expression and function of insulin/insulin-like growth factor I hybrid receptors during differentiation of 3T3-L1 preadipocytes.

Modan-Moses D, Janicot M, McLenithan JC, Lane MD, Casella SJ.

Biochem J. 1998 Aug 1;333 ( Pt 3):825-31.

38.

Oocyte microinjection assay for evaluation of Ras-induced signaling pathways.

Tocque B, Janicot M, Kenigsberg M.

Methods Enzymol. 1995;255:426-35. No abstract available.

PMID:
8524128
39.

Uptake of injected 125I-ricin by rat liver in vivo. Subcellular distribution and characterization of the internalized ligand.

Frénoy JP, Turpin E, Janicot M, Gehin-Fouque F, Desbuquois B.

Biochem J. 1992 May 15;284 ( Pt 1):249-57.

40.

Promoter-cDNA-directed heterologous protein expression in Xenopus laevis oocytes.

Swick AG, Janicot M, Cheneval-Kastelic T, McLenithan JC, Lane MD.

Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1812-6.

41.

Expression of a type I insulin-like growth factor receptor with low affinity for insulin-like growth factor II.

Germain-Lee EL, Janicot M, Lammers R, Ullrich A, Casella SJ.

Biochem J. 1992 Jan 15;281 ( Pt 2):413-7.

42.
43.
44.
45.

Transcriptional repression of the mouse insulin-responsive glucose transporter (GLUT4) gene by cAMP.

Kaestner KH, Flores-Riveros JR, McLenithan JC, Janicot M, Lane MD.

Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1933-7.

46.
47.
48.

Characterization of insulin degradation products generated in liver endosomes: in vivo and in vitro studies.

Clot JP, Janicot M, Fouque F, Desbuquois B, Haumont PY, Lederer F.

Mol Cell Endocrinol. 1990 Sep 10;72(3):175-85.

PMID:
2289630
49.

Effect of insulin-like growth factor I on rat alcohol dehydrogenase in primary hepatocyte culture.

Mezey E, Potter JJ, Mishra L, Sharma S, Janicot M.

Arch Biochem Biophys. 1990 Aug 1;280(2):390-6.

PMID:
2164356
50.

Insulin-receptor tyrosine kinase and glucose transport.

Lane MD, Flores-Riveros JR, Hresko RC, Kaestner KH, Liao K, Janicot M, Hoffman RD, McLenithan JC, Kastelic T, Christy RJ.

Diabetes Care. 1990 Jun;13(6):565-75. Review.

PMID:
2162754

Supplemental Content

Loading ...
Support Center